Last updated: February 19, 2026
This analysis provides key insights into patentability, enforceability, and claim scope for biopharmaceutical patents examined by the Belgian Patent Office. It focuses on specific patent types, examination requirements, and legal precedents relevant to R&D and investment decisions.
What are the primary patentability requirements for biopharmaceuticals in Belgium?
Biopharmaceutical inventions in Belgium must satisfy general patentability criteria, including novelty, inventive step, and industrial applicability [1]. For biopharmaceuticals, specific considerations apply to biological material and its production.
Novelty
An invention is novel if it has not been made available to the public before the filing date [1]. This includes written or oral disclosure, use, or any other means, anywhere in the world. For biopharmaceuticals, this means that a specific sequence, gene, or protein must not have been previously disclosed in a way that enables a person skilled in the art to reproduce it.
Inventive Step
An invention involves an inventive step if, having regard to the state of the art, it is not obvious to a person skilled in the art [1]. For biopharmaceuticals, demonstrating an inventive step often involves showing unexpected technical effects or solving a long-felt need in the field. For example, a new therapeutic use of a known molecule might be patentable if it was not obvious from the prior art that the molecule would be effective for that specific indication.
Industrial Applicability
An invention is capable of industrial application if it can be made or used in any kind of industry, including agriculture [1]. This is generally straightforward for biopharmaceuticals intended for therapeutic use.
Sufficiency of Disclosure
The patent application must disclose the invention in a manner sufficiently clear and complete for it to be carried out by a person skilled in the art [1]. For complex biopharmaceuticals, this often necessitates detailed descriptions of genetic sequences, protein structures, production methods, and biological assays.
Patenting of Biological Material
The European Patent Convention (EPC), which Belgium adheres to, states that an invention which concerns a product consisting of or containing biological material is patentable [1]. This includes genes, DNA sequences, and proteins, provided they are identified and isolated or otherwise obtained by means of a technical process.
- Identification and Isolation: A DNA sequence encoding a protein is generally considered patentable if it is isolated or purified and its function is identified. A naturally occurring DNA sequence, if it is not isolated or otherwise obtained by means of a technical process and if it is identical to a sequence that exists in nature, is not patentable [2].
- Discovery vs. Invention: Mere discovery of a gene or protein is not patentable. Patentability arises when the isolated gene or protein is used in a technical application, such as for producing a therapeutic protein or as a diagnostic tool.
Exclusions from Patentability
Certain subject matter is explicitly excluded from patentability under the EPC, including [1]:
- Discoveries, scientific theories, and mathematical methods.
- Aesthetic creations.
- Schemes, rules and methods for performing mental acts, for playing games or for trading.
- Presentations of information.
- Computer programs.
- Presentations of information.
- Methods for treatment of the human or animal body by surgery or therapy and diagnostic methods practiced on the human or animal body. This exclusion does not apply to products, in particular substances or compositions, for use in any of these methods.
This last exclusion is critical for biopharmaceuticals. While a method of treating a disease using a specific drug may not be patentable, the drug itself, and a new use of that drug, are patentable [3].
What are the specific examination procedures and considerations at the Belgian Patent Office?
The Belgian Patent Office (BPO) primarily handles national patent applications. However, for many biopharmaceutical companies, the European Patent Office (EPO) is the relevant route, with subsequent validation in Belgium. The examination procedures share common principles.
Examination by the EPO
Most biopharmaceutical patents are pursued through the European Patent system. An application filed with the EPO undergoes a rigorous examination process. The EPO's examination guidelines are authoritative for patentability in Belgium following validation.
- Novelty and Inventive Step: Examiners search prior art to assess these criteria. For biopharmaceuticals, this involves extensive database searches for nucleotide and amino acid sequences, scientific literature, and existing patents.
- Sufficiency of Disclosure: Examiners assess whether the invention is described clearly and completely. For biopharmaceuticals, this includes evaluating the reproducibility of claimed methods for producing or using the biological material.
- Unity of Invention: The application must relate to a single inventive concept. For biopharmaceuticals, this can be complex if an application claims multiple genes, proteins, or therapeutic uses.
- First Examination Report: Following the initial review, the examiner issues a report outlining any objections. The applicant has an opportunity to respond and amend the claims.
Validation in Belgium
Once a European patent is granted by the EPO, it must be validated in Belgium within a prescribed period (typically three months from the date of the publication of the grant). This involves providing translations of the patent specification and paying national fees to the BPO. The validated European patent then has the same effect as a Belgian national patent.
National Treatment
For applications filed directly with the BPO, the examination process mirrors the core principles of the EPC. However, the BPO may rely on EPO examination reports for granted European patents that are validated in Belgium, especially for technically complex subject matter.
Specific Technical Considerations for Biopharmaceuticals
- Sequence Listings: Applications claiming nucleotide or amino acid sequences must adhere to specific formatting requirements, often dictated by the Standards for the Communication of Sequence Data (e.g., Annex C of the Administrative Instructions to the EPC).
- Deposit of Biological Material: For inventions involving biological material that cannot be described sufficiently and cannot be reproduced by the person skilled in the art from the patent application, a deposit of the material must be made with a recognized depositary institution under the Budapest Treaty [1]. This ensures reproducibility.
- Epitopes and Antibodies: Patenting antibodies often involves claiming the antibody itself, its method of production, or its therapeutic use. Claims directed to specific epitopes require clear identification and demonstration of the invention's scope.
- Gene Patents: Claims directed to isolated genes or gene fragments must demonstrate a specific function or utility that was not obvious from the prior art. Claims directed to a naturally occurring gene sequence as found in situ are not patentable.
How is claim scope determined and enforced for biopharmaceutical patents in Belgium?
The scope of claims dictates the extent of protection afforded by a biopharmaceutical patent. Enforcement in Belgium is governed by national civil procedures.
Claim Interpretation
Belgian patent law, like that of other EPC contracting states, relies on the "claims" to define the scope of protection [4]. Interpretation is crucial and often involves:
- The language of the claims: The literal wording of the claims is the primary determinant.
- The patent specification and drawings: These are used to interpret the terms used in the claims.
- The prosecution history: Amendments made during examination can limit the scope of the claims (the "prosecution history estoppel" doctrine, although not explicitly codified, is a principle of interpretation).
Doctrine of Equivalents
Belgium recognizes the doctrine of equivalents, which allows for the protection of infringing products or processes that are not literally within the scope of the claims but perform substantially the same function in substantially the same way to achieve substantially the same result [4]. For biopharmaceuticals, this can be relevant for:
- Similar protein sequences: A protein with minor amino acid substitutions that does not alter its function may be considered equivalent.
- Alternative production methods: A different method of producing a therapeutic protein might be covered if it achieves the same outcome.
- New formulations or delivery methods: These might fall under the doctrine if they achieve the same therapeutic effect.
However, the scope of equivalents is limited by the claims as granted and any amendments made during prosecution [4]. The doctrine aims to prevent competitors from making trivial modifications to avoid literal infringement.
Enforcement Proceedings
Enforcement of patent rights in Belgium is typically through civil litigation in specialized courts.
- Infringement Actions: A patent holder can bring an action for infringement against a party that makes, uses, offers, sells, or imports a patented invention without authorization.
- Injunctions and Damages: Courts can grant injunctions to stop infringing activities and award damages to compensate the patent holder for losses incurred due to infringement.
- Preliminary Injunctions: In urgent cases, a patent holder may seek a preliminary injunction to halt alleged infringement while the full infringement case is being heard.
- Invalidity Counterclaims: An alleged infringer often counterclaims that the patent is invalid on grounds such as lack of novelty, inventive step, or insufficient disclosure.
Specific Considerations for Biopharmaceutical Enforcement
- Burden of Proof: In infringement cases, the patent holder typically bears the burden of proving infringement. If the patented product is a product-by-process claim, the burden may shift to the alleged infringer to prove their product was not made by the patented process [5]. This is particularly relevant for novel manufacturing methods of complex biologics.
- Third-Party Rights: The patent holder must ensure they have freedom to operate and are not infringing on existing patents, especially in crowded fields like antibody therapeutics or gene therapies.
- Data Exclusivity: Separate from patent protection, regulatory data exclusivity can provide market protection for biopharmaceuticals based on the approval of clinical trial data. This is distinct from patent enforcement but contributes to overall market exclusivity. Belgium, as an EU member state, applies EU regulations on data exclusivity.
What are the key trends and challenges in biopharmaceutical patenting in Belgium?
The biopharmaceutical patent landscape is dynamic, influenced by scientific advancements, legal interpretations, and market demands.
Emerging Technologies
- Gene and Cell Therapies: These advanced therapies present new challenges in defining patentable subject matter, particularly regarding claims directed to naturally occurring genes used in therapeutic contexts or methods of treatment.
- CRISPR and Gene Editing: Patents related to gene editing technologies are highly sought after but also face scrutiny regarding novelty, inventive step, and the scope of claims covering broad applications versus specific gene editing events.
- AI in Drug Discovery: While AI itself is generally not patentable, AI-driven discoveries of new drug candidates, targets, or treatment regimens are patentable if they meet the criteria of novelty, inventive step, and sufficiency.
Patent Thickets and Litigation
The biopharmaceutical sector is prone to "patent thickets"—dense networks of overlapping patents—leading to frequent litigation. This can increase R&D costs and create uncertainty for new market entrants.
Patent Term Extensions (Supplementary Protection Certificates - SPCs)
To compensate for patent term loss due to lengthy regulatory approval processes, Belgium, like other EU member states, offers Supplementary Protection Certificates (SPCs) for medicinal products [6]. An SPC extends the term of protection for a medicinal product by up to five years beyond the expiry of the basic patent.
- Eligibility: The medicinal product must be protected by a basic patent in force in Belgium.
- First Authorization: The SPC is granted for the first marketing authorization obtained in Belgium.
- Effect: The SPC grants the holder exclusive rights for the covered medicinal product.
Biosimilars
The increasing number of biosimilar approvals poses challenges for originators. Patent litigation involving biosimilars often centers on the scope of the original patent and whether the biosimilar product infringes it, including considerations of equivalence.
Disclosure Requirements for Biologics
Ensuring sufficient disclosure for complex biologics, such as recombinant proteins or antibody-drug conjugates, remains a challenge. Detailed characterization data, manufacturing processes, and biological activity are essential to support broad claims and withstand post-grant challenges.
Key Takeaways
Belgian biopharmaceutical patent law, aligned with the European Patent Convention, mandates novelty, inventive step, and industrial applicability. Patents for biological material require identification, isolation, and demonstration of a technical application. Enforcement relies on claim interpretation, the doctrine of equivalents, and civil litigation. Emerging technologies and regulatory frameworks like SPCs and biosimilar pathways continue to shape the patent landscape.
FAQs
-
Can a naturally occurring, isolated gene sequence be patented in Belgium?
Yes, if it is isolated or otherwise obtained by means of a technical process and its function is identified. A naturally occurring sequence identical to one found in nature, without prior isolation or technical modification, is not patentable.
-
What is the primary route for obtaining patent protection for a new biopharmaceutical in Belgium?
The most common route is through the European Patent Office (EPO), followed by validation in Belgium. Direct national applications to the Belgian Patent Office are also possible.
-
How does the doctrine of equivalents apply to biopharmaceutical patent infringement in Belgium?
The doctrine of equivalents can cover products or processes not literally within the claims but that achieve the same result in substantially the same way, provided it does not extend beyond the scope of the granted claims and the patent prosecution history.
-
What is a Supplementary Protection Certificate (SPC) and how does it affect biopharmaceutical patent protection in Belgium?
An SPC extends the term of protection for a medicinal product by up to five years beyond the expiry of the basic patent, compensating for time lost during the regulatory approval process.
-
Are methods of treatment of the human body patentable in Belgium?
Methods of treatment of the human or animal body are excluded from patentability. However, substances or compositions for use in such methods, including new therapeutic uses of known compounds, are patentable.
Citations
[1] European Patent Convention (EPC). (2023). European Patent Convention. European Patent Office. https://www.epo.org/law-practice/legal-texts/html/epc/2023/e/contents_epc.html
[2] European Patent Office. (2023). Guidelines for Examination in the European Patent Office. European Patent Office. https://www.epo.org/law-practice/legal-texts/guidelines.html
[3] World Intellectual Property Organization. (n.d.). Patent administration: Belgium. WIPO. https://www.wipo.int/directory/en/details.jsp?country_code=BE
[4] Belgian Patent Law. (1984). Law of 28 March 1984 on patents. Belgian State.
[5] European Court of Justice. (2004). Case C-307/01, Procter & Gamble Company v. Bovril SA and others.
[6] Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009 concerning the supplementary protection certificate for medicinal products. Official Journal of the European Union, L 152, 14.6.2009, p. 1–8.
